Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Medtronic PLC — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Medtronic PLC trades at $90.61 (market cap $114.45B). The key difference: Medtronic PLC pays a 3.22% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Medtronic PLC is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | MDT | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $105.35 |
52-Week Low | $92.95 | $73.75 |
Market Cap | — | $114.45B |
Enterprise Value | — | $133.19B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
